We protect your health through science

Investigation

Legionella

Research Lines

Content with Investigacion Inmunología .

Trasplante de órganos

null

Presentación y Regulación Inmunes

null

Inmunología Microbiana e Inmunogenética

1. Análisis de la respuesta innata de mamíferos en la infección por Leishmania.

2. Caracterización inmunoproteómica en :

   a.  Streptococcus suis

   b. Lactococcus garviae

   c. Mycobacterium spp

3. Desarrollo de inmunoensayos analíticos basados en anticuerpos monoclonales (AcM) para detectar y cuantificar antígenos de origen animal, vegetal y microbiano.

4. Desarrollo y caracterización de AcM frente a los componentes del sistema del Complemento. Aplicación diagnóstica.

5. Desarrollo de reactivos de referencia y diseño de inmunoensayos para la evaluación cualitativa y cuantitativa de toxinas clostridiales.

6. Oferta tecnológica de producción de AcM  y policlonales frente a substancias de interés industrial y biomédico.

 

​El grupo está interesado en el estudio de la respuesta inmune desde una perspectiva multidisciplinar que incluye aproximaciones bioquímicas, biotecnológicas, genómicas, inmunoinformáticas y proteómicas, que junto con el uso adicional de modelos in vivo se encaminan al diseño de estrategias terapéuticas frente a diversas enfermedades crónicas, infecciosas y raras que poseen un claro componente inmunológico en su etiología.

 

 

Las principales líneas de investigación que está desarrollando el grupo en la actualidad son:

 

  • * Análisis de las respuestas inmunes celulares frente a patógenos virales y bacterianos, mediante técnicas inmunoproteómicas, modelos in vivo con animales transgénicos y muestras humanas.
  •  
  • Imagen4.jpg

  • * Caracterización de CD69: regulación génica, función reguladora inmune en homeostasis e infección y su uso como diana terapéutica, edición génica por CRISPR en modelos animales y celulares, etc.

imagen CD69.jpg

* Desarrollo de herramientas inmunoinformáticas que permitan analizar la respuesta inmune celular frente a diversos virus de interés sanitario y determinar la eficacia de sus vacunas a nivel de población mundial.

Imagen8.png


* Estudio de las respuestas inmunes celulares frente a enfermedades raras (artritis reactiva y síndrome del linfocito desnudo) y crónicas (espondiloartropatías).

TOC.jpg

 

* Inclusión de componentes del sistema inmune en la fabricación de tejidos humanos, especialmente piel, para uso clínico, farmacéutico y cosmético.

 

  • * Generación de virus recombinantes como vectores vacunales.

Imagen7.png

Inmunología Celular

null

The Immunobiology group has been working for years on the following lines of research:
1) The mechanisms of haematopoietic cell generation throughout ontogeny and the influence that the first haematopoietic cells exert on the innate and adaptive immune system present in the adults. We have identified and characterised a new population of B lymphocytes called B1-Rel (B220lo), which produce high levels of natural IgG/IgA antibodies. We sought to understand their role in the immune response in animal models of infection, analysing their impact on immune cell populations and on the production of soluble mediators (cytokines and immunoglobulins). In this regard, we have evaluated the generation of embryonic megakaryocytes (and their differentiation niches), their functionality and that of platelets, and their influence on haematopoietic development. For lymphoid populations, we have carried out extensive characterisation by flow cytometry and single cell RNA sequencing (scRNAseq) methodology. To carry out these cellomic studies, we have designed complex panels for use in multiparametric phenotypic analysis, and single cell cytometry and RNAseq omics technologies on purified cell populations.


In parallel, we are interested in understanding local immune responses in respiratory infections at times of particular susceptibility due to the fragility of the immune system (childhood and old age), both in mouse animal models, which allow their manipulation, and in humans. 

2) Mouse models studied during neonatal life, in which we evaluated the effect of antibiotic (AB) treatment and addressed the role of TLR receptors in innate, pseudo-innate and adaptive immune cell populations. In these models, we observed that AB administration was able to modulate B-lymphoid populations, as well as their ability to secrete proinflammatory cytokines in culture and their differentiation into plasma cells, with differentiated immunoglobulin repertoires. Furthermore. These effects were mediated through the Toll-like receptor-2 (TLR2).

3) Mouse models with accelerated senescence (SAMP8) and senescent animals (over 20 months of age) to map lymphoid populations and soluble mediators of the immune response (immunoglobulins and cytokines). In these models, the B lymphoid populations (B1Rel and marginal zone B lymphocytes) are observed to be altered, accompanied by an increase in IgG1 with great restriction of their VDJ repertoires.


4) Role of the B1Rel population in animal models of local or systemic infection. We analysed the response to Streptoccoccus pneumoniae (SPN) locally in the lung and systemically in the spleen, as well as the role of TLR4 in these responses.

5) In humans, we are studying immune responses in children with respiratory syncytial virus (RSV) viral primo-infection. In this case we studied the immune response that occurs locally in the nasal mucosa (by analysis of nasal washings, NW) in a cohort of infected children versus healthy controls, stratified by age. We found that lymphomyeloid cells accumulate in these nasal washings in patients with diverse lymphocyte populations, as well as cytokines and immunoglobulins.

6) Analysis and characterisation of extracellular vesicles produced during respiratory infection both in lung supernatants from models of SPN infection and in LN in the case of children with RSV infection.

7) In parallel, we carry out studies of the genetic rearrangements of immunoglobulins and their use in the generation of chimeric receptors for possible use in immunotherapy.

Research projects

Content with Investigacion Inmunología .

 Los proyectos del grupo de los últimos años son los siguientes:

Proyecto “Enfoques inmunoinformaticos e inmunoproteomicos para identificar epitopos bacterianos implicados en la REA: diagnostico temprano y diseño de farmacos” financiado por el Plan Nacional de I+D+i del Ministerio de Ciencia, Innovación y Universidades. Centro Nacional de Microbiología, Instituto de Salud Carlos III. Investigador principal. Año: 2024-2026. Presupuesto Concedido: 225.000 euros. Proyecto PID2023-148729OB-100  financiado por MICIU/AEI/10.13039/501100011033 y por FEDER, UE.


 

Proyecto “La interrelación de CD69 y el procesamiento antigénico en enfermedades infecciosas y autoinmunes" financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año: 2023-2025.

Proyecto “Interacciones génicas y proteicas de CD69 y sus regiones génicas reguladoras con moléculas" inanciado por el Plan Nacional de I+D+i del Ministerio de Ciencia, Innovación y Universidades. Centro Nacional de Microbiología, Instituto de Salud Carlos III. Proyecto PID2021-125757OB-100  financiado por MICIU/AEI/10.13039/501100011033 y por FEDER, UE. 

Proyecto “Nuevas tecnologías de fabricación y optimización de tejidos: la piel como sistema modelo” financiado por el Programa de Actividades de I+D entre grupos de investigación de la Comunidad de Madrid en tecnologías 2018. Año: 2020-2023. Proyecto Coordinado por el Dr. Pablo Acedo de la Universidad Carlos III. 

Proyecto “Estudio de CD69 como diana para mejorar el tratamiento de la leucopania y la movilización de células T de memoria de médula ósea" financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año:2020-2024. 

Proyecto “Diseño racional de una vacuna contra el virus respiratorio sincitial humano” financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año: 2019-2022

Proyecto “Función de CD69 y sus elementos reguladores" financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año: 2017-2022. 

 

Proyecto “Diseño de vacunas recombinantes poliepitópicas para generar respuestas CD8+ contra virus emergentes” financiado por el Plan Nacional de I+D+i del Ministerio de Economía y Competitividad. Año: 2015-2017. 

 

Proyecto “Análisis de los efectos de CD69 dependientes de S1P1 en modelos de infección e inflamación y estudio de su regulación” financiado por el FIS. Año: 2014-2017.

 

Proyecto “ADELVAC: Adenovirus con delecciones epitópicas para vacunación” financiado por el programa INNPACTO del Ministerio de Economía y Competitividad. Centro Nacional de Microbiología, Instituto de Salud Carlos III. Año: 2012-2014. Proyecto Coordinado por el Dr. Manel Cascallo de VCN BIOSCIENCES SL.

 

Proyecto “Diseño de vacunas multiepitópicas recombinantes para aumentar la respuesta inmune celular contra el VRSH” financiado por el Plan Nacional de I+D+i del Ministerio de Ciencia e Innovación. Año: 2012-2014. 

-Project “Induction, differentiation and modulation of resident B lymphocytes in the lung in response to pneumococcus (NEUBLUNG)”. Ministry of Science and Innovation, PID2022-141754OB-I00 Call 2022 "Knowledge Generation Projects". 09/01/2023-08/31/2026. Financed by MICIU/AEI /10.13039/501100011033 and by ERDF, EU. PI: Belén by Andrés Muguruza. CoPI: María Luisa Gaspar Alonso-Vega.


 

-Project." Immune response of the nasal mucosa in childhood bronchiolitis” Instituto de Salud Carlos III-AESI. AESI-PI22CIII/00030 PI: Belén by Andrés Muguruza. CoPI Maria Luisa Gaspar Alonso-Vega. 01/01/2023-12/31/2025..

-Project. BenBedPhar. CA20121, European Union. Antonio Cuadrado. (CNM-ISCIII).10/19/2021-10/18/2025.

-Spanish Association Against Cancer Project “Novel comprehensive immunotherapy to specifically target the malignant clone in Sézary syndrome, an ultra-rare cancer of mature T lymphocytes”, number PROYE20084REGU. PI: José Ramón Regueiro, PI group Maria Luisa Gaspar. 01/01/2021-12/31/2023.

Project “The pulmonary immune system in homeostasis and infection: characterization and function of immature and pseudoinnate lymphoid populations.” MINECO-RETOS RTI2018-099114-B-100. PI: Maria Luisa Gaspar, CoPI: Belén de Andrés 01/01/2019-12/31/2022. Financed by MICIU/AEI /10.13039/501100011033/ and by FEDER A way of making Europe.


 

-Project “New B lymphoid populations: B1-rel pseudoinnate cells, homeostatic maintenance and their response under infection conditions.” MINECO-RETOS SAF2015-70880-R. PI: Maria Luisa Gaspar. 01/01/2016-12/31/2019.


 

-Project “Role of CD19+CD45R lymphocytes- in perinatal immune responses. Implications related to respiratory diseases in neonates. AESI PI14CIII/00049; PI Belén de Andrés. 2015-2018.

-Project “Study of the pseudo-innate population of CD19+CD45R- B lymphocytes in TLR-dependent infection models”. AESI PI11/01733FIS. PI Belén de Andrés. 2012-2015.

-Project." Cellular interactions in the establishment of B lymphoid differentiation niches: role of megakaryocytes and their implications in pathology. MINECO; SAF2012-33916. Maria Luisa Gaspar. 01/01/2013-12/31/2015.

-ISCIII Platforms Project to support R&D&I in Biomedicine and Health Sciences. PT23CIII/00006. 2023. Participating researcher: Isabel Cortegano.

-Research contracts between the Carlos III Health Institute and Inmunotek S.L. for the development of the Bactek-mv130 and Uromune-MV140 study in protection against S. pneumoniae infections. Immunotek. IP: Belen de Andrés 2019-2021.

-Research contract between the Carlos III Health Institute and Inmunotek S.L. “MV130 as a vaccine model based on trained immunity against respiratory infections due to pneumococcus and respiratory syncytial virus”, CAM Call. Industrial Doctorates. IND2023/BMD-27071. PI: Belén by Andrés Muguruza. 12/01/2023-11/30/2026.

- Titulo: “Inmunidad entrenada en trasplante de órganos”.
 Entidad financiadora. Ministerio de Ciencia, Innovación y Universidades
Referencia: Proyecto PID2019-110015RB-I00 financiado por MICIU/AEI/10.13039/501100011033
IP: Jordi Cano Ochando
Fechas de ejecución: 01/06/2020-31/05/2024
Presupuesto: 205.700 €

Los proyectos del grupo de los últimos años son los siguientes:

Proyecto “La interrelación de CD69 y el procesamiento antigénico en enfermedades infecciosas y autoinmunes" financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año: 2023-2025.

Proyecto “Interacciones génicas y proteicas de CD69 y sus regiones génicas reguladoras con moléculas"  financiado por la AEI. Año: 2022-2024.

Proyecto “Nuevas tecnologías de fabricación y optimización de tejidos: la piel como sistema modelo” financiado por el Programa de Actividades de I+D entre grupos de investigación de la Comunidad de Madrid en tecnologías 2018. Año: 2020-2023. Proyecto Coordinado por el Dr. Pablo Acedo de la Universidad Carlos III. 

Proyecto “Estudio de CD69 como diana para mejorar el tratamiento de la leucopania y la movilización de células T de memoria de médula ósea" financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año:2020-2024. 

Proyecto “Diseño racional de una vacuna contra el virus respiratorio sincitial humano” financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año: 2019-2022

Proyecto “Función de CD69 y sus elementos reguladores" financiado por la Acción Estratégica en Salud del Ministerio de Ciencia, Innovación y Universidades. Año: 2017-2022. 

 

Proyecto “Diseño de vacunas recombinantes poliepitópicas para generar respuestas CD8+ contra virus emergentes” financiado por el Plan Nacional de I+D+i del Ministerio de Economía y Competitividad. Año: 2015-2017. 

 

Proyecto “Análisis de los efectos de CD69 dependientes de S1P1 en modelos de infección e inflamación y estudio de su regulación” financiado por el FIS. Año: 2014-2017.

 

Proyecto “ADELVAC: Adenovirus con delecciones epitópicas para vacunación” financiado por el programa INNPACTO del Ministerio de Economía y Competitividad. Centro Nacional de Microbiología, Instituto de Salud Carlos III. Año: 2012-2014. Proyecto Coordinado por el Dr. Manel Cascallo de VCN BIOSCIENCES SL.

 

Proyecto “Diseño de vacunas multiepitópicas recombinantes para aumentar la respuesta inmune celular contra el VRSH” financiado por el Plan Nacional de I+D+i del Ministerio de Ciencia e Innovación. Año: 2012-2014. 

Publications

Sort
Category

Epidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-beta-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain

Villalón P, Valdezate S, Medina-Pascual MJ, Carrasco G, Vindel A, Saez-Nieto JA. Epidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-beta-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain. J Antimicrob Chemother. 2013;68(3):550-3.

PUBMED DOI

Shortcomings of the commercial MALDI-TOF MS database and use of MLSA as an arbiter in the identification of Nocardia species

Carrasco G, de Dios Caballero J, Garrido N, Valdezate S, Cantón R, Sáez-Nieto JA. Shortcomings of the commercial MALDI-TOF MS database and use of MLSA as an arbiter in the identification of Nocardia species. Front Microbiol. 2016 21;7:542.

PUBMED DOI

Kinetics of the invasion and egress processes of Babesia divergens, observed by time-lapse video microscopy.

Sevilla E; González LM; Luque D; Gray J; Montero E. 2018. Kinetics of the invasion and egress processes of Babesia divergens, observed by time-lapse video microscopy. Scientific Reports. 8:14116.DOI: 10.1038/s41598-018-32349-7

PUBMED DOI

Misdiagnosis of Babesiosis as Malaria, Equatorial Guinea, 2014.

2. Arsuaga M; González LM; Salvador Padial E; Woubshet Dinkessa A; Sevilla E; Trigo E; Puente S; Gray J; Montero E. 2018. Misdiagnosis of Babesiosis as Malaria, Equatorial Guinea, 2014. Emerging Infectious Diseases.24-8, pp.1588-1589.

PUBMED DOI

A fatal case of Babesia divergens infection in Northwestern Spain

3. Asensi V; González LM; Fernández-Suárez J; Sevilla E; Navascués RÁ; Suárez ML; Lauret ME; Bernardo A; Carton JA; Montero E. 2018. A fatal case of Babesia divergens infection in Northwestern Spain. Ticks Tick Borne Dis.9-3, pp.730-734.

PUBMED DOI

First report of Babesia microti-caused babesiosis in Spain.

Arsuaga M*; Gonzalez LM*; Lobo CA; Calle F; Bautista JM; Azcárate IG; Puente S; Montero E. 2016. First report of Babesia microti-caused babesiosis in Spain. Vector Borne Zoonotic Dis.16-10, pp.677-679. (*)= contribuyeron igualmente en este trabajo.

PUBMED DOI

First record of Babesia sp. in Antarctic penguins.

5. Montero E; González LM; Chaparro A; Benzal J; Bertellotti M; Masero JA; Colominas-Ciuró R; Vidal V; Barbosa A. 2016. First record of Babesia sp. in Antarctic penguins. Ticks Tick Borne Dis.7-3, pp.498-501.

PUBMED DOI

Ultrastructure of the Babesia divergens free merozoite

6. Del Carmen Terrón M; González-Camacho F; González LM; Luque D; Montero E. 2016. Ultrastructure of the Babesia divergens free merozoite.Ticks Tick Borne Dis.7-6, pp.1274-1279.

PUBMED DOI

First report of Babesia divergens infection in an HIV patient

7. González LM; Castro E; Lobo CA; Richart A; Ramiro R; González-Camacho F; Luque D; Velasco AC; Montero E. 2015. First report of Babesia divergens infection in an HIV patient. Int J Infect Dis. 33:202-4.

PUBMED DOI

Severe babesiosis in immunocompetent man, Spain

9. González LM, Rojo S, González-Camacho F, Luque D, Lobo CA, Montero E. 2014. Severe babesiosis in immunocompetent man, Spain. Emerging Infectious Disease. 20(4):724-726.

PUBMED DOI

The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets

Castro E, González LM, Rubio JM, Ramiro R, Gironés N, Montero E. 2014. The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion. 54(9): 2207-2216.

PUBMED DOI

Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses

Olmedillas E, Cano O, Martinez I, Luque D, Terron MC, McLellan JS, et al. Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses. EMBO Mol Med. 2018;10(2):175-87.

PUBMED DOI

Ultrastructure of the Babesia divergens free merozoite

Terrón M.C, González-Camacho F., González L.M., Luque D.*, Montero E. 2016. Ultrastructure of the Babesia divergens free merozoite. Ticks Tick Borne Diseases. 7(6):1274-1279. *Corresponding author. IF: 3.23, Q1.

PUBMED DOI

High-Quality Draft Genome of Babesia divergens, the Etiological Agent of Cattle and Human Babesiosis.

8. Cuesta I; González LM; Estrada K; Grande R; Zaballos A; Lobo CA; Barrera J; Sanchez-Flores A; Montero E. 2014. High-Quality Draft Genome of Babesia divergens, the Etiological Agent of Cattle and Human Babesiosis. Genome Announcement. 2: e01194-14.

PUBMED DOI

Horizontal gene transmission of the cfr gene to MRSA and Enterococcus: role of Staphylococcus epidermidis as a reservoir and alternative pathway for the spread of linezolid resistance.

Horizontal gene transmission of the cfr gene to MRSA and Enterococcus: role of Staphylococcus epidermidis as a reservoir and alternative pathway for the spread of linezolid resistance. Cafini F, Nguyen le TT, Higashide M, Román F, Prieto J, Morikawa K. J Antimicrob Chemother. 2016 Mar;71(3):587-92.

PUBMED

Emergence of linezolid-resistant coagulase-negative staphylococci in an intensive care unit.

Emergence of linezolid-resistant coagulase-negative staphylococci in an intensive care unit. Balandin B, Lobo B, Orden B, Román F, García E, Martínez R, Valdivia M, Ortega A, Fernández I, Galdos P. Infect Dis (Lond). 2016;48(5):343-9.

PUBMED

Clinical, microbiological, and molecular characterization of pediatric invasive infections by Streptococcus pyogenes in Spain in a context of global outbreak

Ramírez de Arellano E, Saavedra-Lozano J, Villalón P, Jové-Blanco A, Grandioso D, Sotelo J, Gamell A, González-López JJ, Cervantes E, Gónzalez MJ, Rello-Saltor V, Esteva C, Sanz-Santaeufemia F, Yagüe G, Manzanares Á, Brañas P, Ruiz de Gopegui E, Carrasco-Colom J, García F, Cercenado E, Mellado I, Del Castillo E, Pérez-Vazquez M, Oteo-Iglesias J, Calvo C; Spanish PedGAS-Net/CIBERINFEC GAS Study Group. Clinical, microbiological, and molecular characterization of pediatric invasive infections by Streptococcus pyogenes in Spain in a context of global outbreak. mSphere. 2024 Mar 26;9(3):e0072923

PUBMED DOI

Co-occurrence of the cephalosporinase cepA and carbapenemase cfiA genes in a Bacteroides fragilis division II strain, an unexpected finding

Valdezate S, Medina-Pascual MJ, Villalón P, Garrido N, Monzón S, Cuesta I, Cobo F (2024). Co-occurrence of the cephalosporinase cepA and carbapenemase cfiA genes in a Bacteroides fragilis division II strain, an unexpected finding. J Antimicrobial Chem. 2024 Jul 1;79(7):1683-1687

PUBMED DOI

Exploring the genetic background of the botulism neurotoxin BoNT/B2 in Spain

Valdezate S, Carrasco G, Medina MJ, Garrido N, Del Pino S, Valiente M, Pallarés MP, Villalon P. (2023). Exploring the genetic background of the botulism neurotoxin BoNT/B2 in Spain. Microbiol Spectr. Sep 26;11(5):e0238023

PUBMED DOI

Focusing on Gordonia Infections: Distribution, Antimicrobial Susceptibilities and Phylogeny

Pino-Rosa S, Medina-Pascual MJ, Carrasco G, Garrido N, Villalón P, Valiente M, Valdezate S. (2023). Focusing on Gordonia Infections: Distribution, Antimicrobial Susceptibilities and Phylogeny. Antibiotics (Basel). 26;12(11):1568

PUBMED DOI

Botulism in Spain: Epidemiology and Outcomes of Antitoxin Treatment, 1997-2019

Peñuelas M, Guerrero-Vadillo M, Valdezate S, Zamora MJ, Leon-Gomez I, Flores-Cuéllar Á, Carrasco G, Díaz-García O, Varela C. (2022). Botulism in Spain: Epidemiology and Outcomes of Antitoxin Treatment, 1997-2019. Toxins (Basel). 20;15(1):2

PUBMED DOI

Invasive Streptococcus pyogenes disease in Spain: a microbiological and epidemiological study covering the period 2007-2019

Villalón P, Sáez-Nieto JA, Rubio-López V, Medina-Pascual MJ, Garrido N, Carrasco G, Pino-Rosa S, Valdezate S. (2021). Invasive Streptococcus pyogenes disease in Spain: a microbiological and epidemiological study covering the period 2007-2019. Eur J Clin Microbiol Infect Dis. 2021 Nov;40(11):2295-2303

PUBMED DOI

ANISERP: a new serpin from the parasite Anisakis simplex.

Valdivieso E, Perteguer MJ, Hurtado C, Campioli P, Rodríguez E, Saborido A, Martínez-Sernández V, Gómez-Puertas P, Ubeira FM, Gárate T. ANISERP: a new serpin from the parasite Anisakis simplex.Parasit Vectors. 2015 Jul 28;8:399.

PUBMED DOI

Revisiting the Ancylostoma caninum secretome provides new information on hookworm-host interactions.

Morante T, Shepherd C, Constantinoiu C, Loukas A, Sotillo J. Revisiting the Ancylostoma caninum secretome provides new information on hookworm-host interactions. Proteomics. 2017 Dec;17(23-24).

PUBMED DOI

Hookworm secreted extracellular vesicles interact with host cells and prevent inducible colitis in mice.

Eichenberger RM, Ryan S, Jones L, Buitrago G, Polster R, Montes de Oca M, Zuvelek J, Giacomin PR, Dent LA, Engwerda CR, Field MA, Sotillo J, Loukas A. Hookworm secreted extracellular vesicles interact with host cells and prevent inducible colitis in mice. Front Immunol. 2018 Apr 30;9:850.

PUBMED DOI

HDP2: a ribosomal DNA (NTS-ETS) sequence as a target for species-specific molecular diagnosis of intestinal taeniasis in humans.

Flores MD, Gonzalez LM, Hurtado C, Motta YM, Domínguez-Hidalgo C, Merino FJ, Perteguer MJ, Gárate T. HDP2: a ribosomal DNA (NTS-ETS) sequence as a target for species-specific molecular diagnosis of intestinal taeniasis in humans. Parasit Vectors. 2018 Feb 27;11(1):117. doi: 10.1186/s13071-018-2646-6.

PUBMED DOI

Antibody responses to chimeric peptides derived from parasite antigens in mice and other animal species.

Orbegozo-Medina RA, Martínez-Sernández V, Folgueira I, Mezo M, González-Warleta M, Perteguer MJ, Romarís F, Leiro JM, Ubeira FM. Antibody responses to chimeric peptides derived from parasite antigens in mice and other animal species. Mol Immunol. 2018 Dec 17;106:1-11.

PUBMED DOI

Comparison of T24H-his, GST-T24H and GST-Ts8B2 recombinant antigens in western blot, ELISA and multiplex bead-based assay for diagnosis of neurocysticercosis.

Hernández-González A, Noh J, Perteguer MJ, Gárate T, Handali S. Comparison of T24H-his, GST-T24H and GST-Ts8B2 recombinant antigens in western blot, ELISA and multiplex bead-based assay for diagnosis of neurocysticercosis. Parasit Vectors. 2017 May 15;10(1):237.

PUBMED DOI

Characterization of Trichuris muris secreted proteins and extracellular vesicles provides new insights into host-parasite communication.

Eichenberger RM, Talukder MH, Field MA, Wangchuk P, Giacomin P, Loukas A, Sotillo J. Characterization of Trichuris muris secreted proteins and extracellular vesicles provides new insights into host-parasite communication. J Extracell Vesicles. 2018 Jan 21;7(1):1428004.

PUBMED DOI

Evaluation of onchocerciasis seroprevalence in Bioko Island (Equatorial Guinea) after years of disease control programmes.

Hernández-González A, Moya L, Perteguer MJ, Herrador Z, Nguema R, Nguema J, Aparicio P, Benito A, Gárate T. Evaluation of onchocerciasis seroprevalence in Bioko Island (Equatorial Guinea) after years of disease control programmes. Parasit Vectors. 2016 Sep 20;9(1):509.

PUBMED DOI

Changes in protein expression after treatment with Ancylostoma caninum excretory/secretory products in a mouse model of colitis.

Sotillo J, Ferreira I, Potriquet J, Laha T, Navarro S, Loukas A, Mulvenna J. Changes in protein expression after treatment with Ancylostoma caninum excretory/secretory products in a mouse model of colitis. Sci Rep. 2017 Feb 13;7:41883.

PUBMED DOI

Fasciola spp: Mapping of the MF6 epitope and antigenic analysis of the MF6p/HDM family of heme-binding proteins.

Martínez-Sernández V, Perteguer MJ, Mezo M, González-Warleta M, Gárate T, Valero MA, Ubeira FM. Fasciola spp: Mapping of the MF6 epitope and antigenic analysis of the MF6p/HDM family of heme-binding proteins. PLoS One. 2017 Nov 21;12(11):e0188520.

PUBMED DOI

Accumulation of endogenous free radicals is required to induce titan-like cell formation in Cryptococcus neoformans

Irene García-Barbazán, Alba Torres-Cano, Rocío García-Rodas, Martin Sachse, Daniel Luque, Diego Megías, Oscar Zaragoza. mBio. 2024 Jan 16;15(1):e0254923

PUBMED DOI

An alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains

15. Alcazar-Fuoli L, Buitrago M, Gomez-Lopez A, Mellado E. An alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains. Virulence. 2015;6(4):376-84. doi: 10.1080/21505594.2015.1025192. PMID: 26065322.

PUBMED DOI

Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study

Sempere J, Llamosí M, López Ruiz B, Del Río I, Pérez-García C, Lago D, Gimeno M, Coronel P, González-Camacho F, Domenech M, Yuste J. Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study. Lancet Microbe. 2022 Oct;3(10):e744-e752.

PUBMED DOI

Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains

Tirado-Vélez JM, Carreño D, Sevillano D, Alou L, Yuste J, de la Campa AG. Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains. Antibiotics. 2021 May 13;10(5):573.

PUBMED DOI

Minilungs from Human Embryonic Stem Cells to Study the Interaction of Streptococcus pneumoniae with the Respiratory Tract

Sempere J, Rossi SA, Chamorro-Herrero I, González-Camacho F, de Lucas MP, Rojas-Cabañeros JM, Taborda CP, Zaragoza Ó, Yuste J, Zambrano A. Minilungs from Human Embryonic Stem Cells to Study the Interaction of Streptococcus pneumoniae with the Respiratory Tract. Microbiol Spectr. 2022 Jun 29;10(3):e0045322

PUBMED DOI

A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004-20 in Spain

Sempere J, González-Camacho F, Domenech M, Llamosí M, Del Río I, López-Ruiz B, Gimeno M, Coronel P, Yuste J. A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004-20 in Spain. J Antimicrob Chemother. 2022 Mar 31;77(4):1045-1051.

PUBMED DOI

Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era

de Miguel S, Domenech M, González-Camacho F, Sempere J, Vicioso D, Sanz JC, Comas LG, Ardanuy C, Fenoll A, Yuste J. Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era. Clin Infect Dis. 2021 Dec 6;73(11):e3778-e3787

PUBMED DOI

Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis

7. Mata E, Tarancón R, Guerrero C, Moreo E, Moreau F, Uranga S, Gomez AB, Marinova D, Domenech M, Gonzalez-Camacho F, Monzon M, Badiola J, Dominguez-Andres J, Yuste J, Anel A, Peixoto A, Martin C, Aguilo N. Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis. Sci Immunol. 2021 Sep 24;6(63):eabc2934

PUBMED DOI

Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System

Corsini B, Aguinagalde L, Ruiz S, Domenech M, Yuste J. Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System. Vaccines. 2021 Feb 23;9(2):186.

PUBMED DOI

Physiologic and transcriptomic effects triggered by overexpression of wild type and mutant DNA topoisomerase I in Streptococcus pneumoniae

García-López M, Hernández P, Megias D, Ferrándiz MJ, de la Campa AG. Int J Mol Sci. 2023; 24:15800.

PUBMED DOI

StaR Is a positive regulator of topoisomerase I activity involved in supercoiling maintenance in Streptococcus pneumoniae

de Vasconcelos Junior AA, Tirado-Vélez JM, Martín-Galiano AJ, Megias D, Ferrándiz MJ, Hernández P, Amblar M, de la Campa AG. Int J Mol Sci. 2023; 24:5973.

PUBMED DOI

Role of PatAB transporter in efflux of levofloxacin in Streptococcus pneumoniae

Amblar M, Zaballos A, de la Campa AG. Antibiotics. 2022; 17:1837.

PUBMED DOI

Seconeolitsine, the novel inhibitor of DNA topoisomerase I, protects against invasive pneumococcal disease caused by fluoroquinolone-resistant strains.

Tirado-Vélez JM, Carreño D, Sevillano D, Alou L, Yuste J, de la Campa AG. Antibiotics 2021; 10:573.

PUBMED DOI

Genome-wide proximity between RNA polymerase and DNA topoisomerase I supports transcription in Streptococcus pneumoniae

Ferrándiz M-J, Hernández P, de la Campa AG. PLoS Genet. 2021; 17:e1009542.

PUBMED DOI

A Small Non-Coding RNA Modulates Expression of Pilus-1 Type in Streptococcus pneumoniae

Acebo P, Herranz C, Bernal-Espenberger L, Gómez-Sanz A, Terron MC, Luque D and Amblar M. Microorganisms. 2021; 9:1883.

PUBMED DOI

Reactive oxygen species production is a major factor directing the post-antibiotic effect of fluoroquinolones in Streptococcus pneumoniae

García MT, Valenzuela MV, Ferrándiz MJ, de la Campa AG. Antimicrob Agents Chemother. 2019; 63:e00737-19.

PUBMED DOI

HU of Streptococcus pneumoniae is essential for the preservation of DNA supercoiling

Ferrándiz MJ, Carreño D, Ayora S, de la Campa AG. Front Microbiol. 9:493 (2018).

PUBMED DOI

Boldine-derived alkaloids inhibit the activity of DNA topoisomerase I and growth of Mycobacterium tuberculosis.

García MT, Carreño D, Tirado-Vélez JM, Ferrándiz MJ, Rodrigues L, Gracia B, Amblar M, Ainsa JA*, de la Campa AG. Front Microbiol. 9:493 (2018).

PUBMED DOI

Absence of tmRNA has a protective effect against fluoroquinolones in Streptococcus pneumoniae

Brito L, Wilton J, Ferrándiz MJ, Gómez-Sanz A, de la Campa AG, Amblar M. Front. Microbiol. 7:2164 (2017).

PUBMED DOI

Bridging chromosomal architecture and pathophysiology of Streptococcus pneumoniae

Martín-Galiano AJ, Ferrándiz MJ, de la Campa AG. Genome Biol Evol. 2017; 9:350-361.

PUBMED DOI

Upregulation of the PatAB transporter confers fluoroquinolone resistance to Streptococcus pseudopneumoniae

Alvarado M, Martín-Galiano AJ, Ferrándiz MJ, Zaballos A, de la Campa AG. Front Microbiol. 8:2074 (2017).

PUBMED DOI

A novel typing method for Streptococcus pneumoniae using selected surface proteins

Domenech A, Moreno J, Ardanuy C, Liñares J, de la Campa AG, Martin-Galiano AJ. Front Microbiol. 2016; 31;7:420.

PUBMED DOI

An increase in negative supercoiling in bacteria reveals topology-reacting gene clusters and a homeostatic response mediated by the DNA topoisomerase I gene

Ferrándiz MJ, Martín-Galiano AJ, Arnanz C, Camacho-Soguero I, Tirado-Vélez JM, de la Campa AG. 2016. Nucl Acids Res. 44:7292-7303 (2016).

PUBMED DOI

Reactive oxygen species contribute to the bactericidal effects of the fluoroquinolone moxifloxacin in Streptococcus pneumoniae

Ferrándiz MJ, Martín-Galiano AJ, Arnanz C, Zimmerman T, de la Campa AG. Antimicrob Agents Chemother. 60:409-417 (2016).

PUBMED DOI

The fluoroquinolone levofloxacin triggers the transcriptional activation of iron transport genes that contribute to cell death in Streptococcus pneumoniae.

Ferrándiz MJ, de la Campa AG. Antimicrob Agents Chemother. 58:247-257 (2014)

PUBMED DOI

Fluoroquinolone-resistant pneumococci: dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006

Domenech A, Tirado-Vélez JM, Fenoll A, Ardanuy C, Yuste J, Liñares J, de la Campa AG. Antimicrob Agents Chemother. 58:2393-2399 (2014).

PUBMED DOI

The balance between gyrase and topoisomerase I activities determines levels of supercoiling, nucleoid compaction, and viability in bacteria

García-López M, Megias D, Ferrándiz MJ, de la Campa AG. Front Microbiol. 2023; 11;1094692.

PUBMED DOI

Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling.

Bodega-Mayor I, Delgado-Wicke P, Arrabal A, Alegría-Carrasco E, Nicolao-Gómez A, Jaén-Castaño M, Espadas C, Dopazo A, Martín-Gayo E, Gaspar ML, de Andrés B, Fernández-Ruiz E. Cell Mol Life Sci. 2024 Apr 29;81(1):199.

PUBMED DOI

Content with Investigacion Inmunología .

List of staff

Additional Information

Content with Investigacion Inmunología .